出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2022年2月
臨床試験市場 : フェーズ（フェーズI、II、III）、サービスタイプ（位置同定、ラボサービス、分散型臨床試験）、治療領域（腫瘍学、感染症）、用途（ワクチン、細胞、遺伝子治療） – 2026年までの世界予測
Clinical Trials Market by Phase (Phase I, II, III), Service Type (Site Identification, Laboratory Services, Decentralized Clinical Trial), Therapy Area (Oncology, Infectious Disease), and Application (Vaccines, Cell & Gene Therapy) – Global Forecast to 2026
| ページ数 | 306 |
| 図表数 | 383 |
| 種別 | 英文調査報告書 |
| 価格 |
The clinical trials market is projected to reach USD 52.0 billion by 2026 from USD 38.7 billion in 2021, at a CAGR of 6.1% during the forecast period, owing to increasing number of clinical trials, rising prevalence of orphan & rare diseases and high cost of in-house drug development.
“By service type, the laboratory services segment accounted for the largest share of the clinical trials market”
Based on service type, the clinical trials market is segmented into protocol designing, site identification, patient recruitment, laboratory services, bioanalytical testing, analytical testing, clinical trial supply & logistic services, decentralized clinical services, clinical trial data management services, medical device testing services, and other services. Laboratory services is the leading segment of clinical trial services market, this can be attributed to the increasing preference of clinical research professionals to outsource such services.
“Asia Pacific: The fastest-growing region in the clinical trials market.”
The Asia Pacific market is projected to grow at the highest CAGR during the forecast period. The high growth rate in this region can be attributed to the fast-growing pharmaceutical industry in the region, favorable government policies, the increasing number of pharmaceutical companies establishing manufacturing facilities in the region, and the lower cost of clinical trials in the region.
“North America: The North America region accounted for the largest share of the clinical trials market”
North America accounted for the largest share of the clinical trials market. Rapid growth in the biosimilar and biologics markets and an increase in clinical trial activity are the major factors driving the market growth.
Breakdown of primaries
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:
By Respondent– Supply Side- 40%, Demand Side- 60%
By Designation— Executives- 25%, CXOs & Directors–30%, Managers – 45%
By Region— North America – 40%, Europe – 25%, APAC – 20%, LATAM- 10%, MEA- 5%
The clinical trials market is dominated by a few globally established players such as including IQVIA (US), LabCorp (US), Charles River Laboratories (US), WuXi AppTec (China), Syneos Health (US), Parexel International (US), PPD (US), and ICON Plc (US). Other players operating in the market are Medpace Holdings (US), SGS (Switzerland), PSI CRO AG (US), Axcent Advanced Analytics (US), BIO Agile Therapeutics (US), Firma Clinical Research (US), Acculab Life Sciences (US), Azelix (US), CTserv (US), Pepgra (UK), and Dove Quality Solutions (US), Novotech Health Holding (Australia), Geneticist Inc. (US), Linical Americas (US), Frontage Holding Corporation (US), and Celerion (US).
Research Coverage:
The report segments the clinical trials market based on region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa), Phase (Phase I, Phase II, Phase III, Phase IV), Service Type (Protocol Designing, Site Identification, Patient Recruitment, Laboratory Services, Bioanalytical Testing Services (Cell-based Assays, Virology Testing, Method Development, Optimization & Validation, Serology, Immunogenicity, & Neutralizing Antibodies, Biomarker Testing Services, PK/PD Testing Services, Other Bioanalytical Testing Services), Analytical Testing Services, Clinical Trial Supply & Logistic Services, Decentralized Clinical Services, Clinical Trial Data Management Services, Medical Device Testing Services, Other Clinical Trial Services), Therapy Area (Oncology, Infectious Diseases, Cardiology, Neurology, Women’s Health, Genetic Diseases, Immunology, and Other Therapy Areas), Application (Vaccine, Cell & Gene Therapy, Small Molecules, Other Applications)
The report also provides a comprehensive review of market drivers, challenges, and opportunities in the clinical trials market.
Key Benefits of Buying the Report:
The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the clinical trials market and provides them information on key market drivers, challenges, and opportunities.
目次
1 INTRODUCTION 40
1.1 OBJECTIVES OF THE STUDY 40
1.2 MARKET DEFINITION 40
1.2.1 INCLUSIONS & EXCLUSIONS 40
1.3 MARKET SCOPE 41
FIGURE 1 CLINICAL TRIALS MARKET 41
1.3.1 YEARS CONSIDERED FOR THE STUDY 42
1.4 CURRENCY 42
1.5 LIMITATIONS 42
1.6 STAKEHOLDERS 43
1.7 SUMMARY OF CHANGES 43
2 RESEARCH METHODOLOGY 44
2.1 RESEARCH DATA 44
FIGURE 2 RESEARCH DESIGN 44
2.1.1 SECONDARY DATA 45
2.1.2 PRIMARY DATA 46
FIGURE 3 CLINICAL TRIALS MARKET: BREAKDOWN OF PRIMARIES 46
2.2 MARKET SIZE ESTIMATION 47
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF CLINICAL TRIALS IN THE MARKET 47
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2020 48
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2020 48
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 50
FIGURE 7 CLINICAL TRIALS MARKET: CAGR PROJECTIONS, 2021–2026 50
FIGURE 8 CLINICAL TRIALS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES 51
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 51
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 53
FIGURE 10 DATA TRIANGULATION METHODOLOGY 53
2.5 INSIGHTS FROM PRIMARIES 54
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS 54
2.6 RESEARCH ASSUMPTIONS 54
2.6.1 COVID-19 SPECIFIC ASSUMPTIONS 55
2.7 RISK ANALYSIS 55
3 EXECUTIVE SUMMARY 56
FIGURE 12 CLINICAL TRIALS MARKET, BY PHASE, 2021 VS. 2026 (USD BILLION) 56
FIGURE 13 CLINICAL TRIALS MARKET, BY THERAPY AREA, 2021 VS. 2026 (USD BILLION) 57
FIGURE 14 CLINICAL TRIALS MARKET, BY APPLICATION, 2021 VS. 2026 (USD BILLION) 57
FIGURE 15 CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021 VS. 2026 (USD BILLION) 58
FIGURE 16 GEOGRAPHICAL SNAPSHOT: CLINICAL TRIALS MARKET 59
4 PREMIUM INSIGHTS 60
4.1 CLINICAL TRIALS MARKET OVERVIEW 60
FIGURE 17 RISING INVESTMENTS IN THE PHARMACEUTICAL INDUSTRY TO DRIVE
THE MARKET GROWTH 60
4.2 NORTH AMERICA: CLINICAL TRIALS MARKET SHARE, BY PHASE & COUNTRY (2020) 61
FIGURE 18 PHASE III SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN CLINICAL TRIALS MARKET IN 2020 61
4.3 CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICE TYPE,
2021 VS. 2026 (USD BILLION) 62
FIGURE 19 CELL-BASED ASSAY SEGMENT CONTINUES TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 62
5 MARKET OVERVIEW 63
5.1 INTRODUCTION 63
5.2 MARKET DYNAMICS 63
FIGURE 20 CLINICAL TRIALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 63
TABLE 1 CLINICAL TRIALS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 64
5.2.1 DRIVERS 64
5.2.1.1 Increasing investment in pharmaceutical R&D 64
FIGURE 21 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026 65
FIGURE 22 ACTIVE PHARMACEUTICAL PIPELINE, 2011–2021 65
5.2.1.2 Increasing number of clinical trials 66
FIGURE 23 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2021) 66
5.2.1.3 High cost of in-house drug development 66
FIGURE 24 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION) 67
5.2.1.4 Rising prevalence of orphan and rare diseases 67
5.2.2 OPPORTUNITIES 68
5.2.2.1 Growth in drugs and biologics market despite COVID-19 pandemic 68
FIGURE 25 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2001–2020) 68
TABLE 2 LIST OF BIOLOGICS APPROVED BY US FDA, 2020 68
5.2.2.2 Rising demand for specialized testing services among end users 69
5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies 70
5.2.3 CHALLENGES 70
5.2.3.1 Shortage of skilled professionals for clinical trials 70
5.2.3.2 Requirement of unique analytical testing approaches for innovative drug molecules 70
5.2.4 MARKET TRENDS 71
5.2.4.1 Adoption of artificial intelligence-based tools for drug discovery 71
5.2.4.2 Increasing outsourcing activities in emerging Asian economies 71
5.2.4.3 Integrated end-to-end R&D service solutions 73
5.3 RANGES/SCENARIOS 73
FIGURE 26 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE CLINICAL TRIALS MARKET 73
5.4 IMPACT OF COVID-19 ON CLINICAL TRIALS MARKET 74
5.5 PORTER’S FIVE FORCES ANALYSIS 75
TABLE 3 CLINICAL TRIALS MARKET: PORTER’S FIVE FORCES ANALYSIS 75
5.5.1 THREAT OF NEW ENTRANTS 75
5.5.2 THREAT OF SUBSTITUTES 75
5.5.3 BARGAINING POWER OF BUYERS 75
5.5.4 BARGAINING POWER OF SUPPLIERS 76
5.5.5 DEGREE OF COMPETITION 76
5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 76
FIGURE 27 REVENUE SHIFT & NEW POCKETS FOR CLINICAL TRIAL SERVICE PROVIDERS 76
5.7 ECOSYSTEM ANALYSIS 77
FIGURE 28 ECOSYSTEM ANALYSIS: CLINICAL TRIALS MARKET 77
TABLE 4 SUPPLY CHAIN ECOSYSTEM 78
5.8 REGULATORY ANALYSIS 79
6 CLINICAL TRIALS MARKET, BY PHASE 82
6.1 INTRODUCTION 83
TABLE 5 CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 83
FIGURE 29 DRUGS IN THE PIPELINE, BY DEVELOPMENT PHASE, 2019 VS. 2020 84
6.2 CLINICAL TRIALS PLANNING AND DESIGNING SOLUTION 84
FIGURE 30 CLINICAL TRIAL PLANNING & DESIGNING 84
6.3 PHASE I 87
6.3.1 ROBUST PIPELINE OF PHARMACEUTICAL COMPANIES DRIVES THE GROWTH OF THIS SEGMENT 87
TABLE 6 EXAMPLES OF PHASE I STUDY OF DRUGS 87
TABLE 7 PHASE I CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION) 88
TABLE 8 NORTH AMERICA: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 88
TABLE 9 EUROPE: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 88
TABLE 10 ASIA PACIFIC: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 89
6.4 PHASE II 89
6.4.1 LONG DURATION OF PHASE II STUDIES PROVIDES GROWTH OPPORTUNITIES FOR CROS 89
TABLE 11 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES 89
TABLE 12 PHASE II CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION) 90
TABLE 13 NORTH AMERICA: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 90
TABLE 14 EUROPE: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 91
TABLE 15 ASIA PACIFIC: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 91
6.5 PHASE III 92
6.5.1 RISING COSTS OF PHASE III TRIALS INCREASES THE DEMAND FOR COST-EFFECTIVE CLINICAL RESEARCH SERVICES 92
TABLE 16 EXAMPLES OF DRUGS THAT HAVE COMPLETED THE PHASE III STUDY 92
TABLE 17 PHASE III CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION) 93
TABLE 18 NORTH AMERICA: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 93
TABLE 19 EUROPE: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 93
TABLE 20 ASIA PACIFIC: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 94
6.6 PHASE IV 94
6.6.1 RISING NUMBER OF CLINICAL RESEARCH ENTITIES PROVIDING POST-MARKETING SURVEILLANCE TO DRIVE THE SEGMENT GROWTH 94
TABLE 21 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES 94
TABLE 22 PHASE IV CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION) 95
TABLE 23 NORTH AMERICA: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 95
TABLE 24 EUROPE: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 95
TABLE 25 ASIA PACIFIC: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 96
7 CLINICAL TRIALS MARKET, BY SERVICE TYPE 97
7.1 INTRODUCTION 98
TABLE 26 CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION) 98
7.2 PROTOCOL DESIGNING 99
7.2.1 PROTOCOL DESIGNING SERVICES SERVE AS AN EFFECTIVE STRATEGY TO ENSURE RAPID & EFFECTIVE PLANNING FOR CLINICAL TRIAL STUDIES 99
TABLE 27 PROTOCOL DESIGNING MARKET, BY REGION, 2019–2026 (USD BILLION) 99
TABLE 28 NORTH AMERICA: PROTOCOL DESIGNING MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 100
TABLE 29 EUROPE: PROTOCOL DESIGNING MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 100
TABLE 30 ASIA PACIFIC: PROTOCOL DESIGNING MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 100
7.3 SITE IDENTIFICATION 101
7.3.1 NEW DIGITAL TECHNOLOGIES THAT ENABLE DATA VARIABILITY ENHANCES SITE IDENTIFICATION SERVICE EFFICACY 101
TABLE 31 SITE IDENTIFICATION MARKET, BY REGION, 2019–2026 (USD BILLION) 101
TABLE 32 NORTH AMERICA: SITE IDENTIFICATION MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 102
TABLE 33 EUROPE: SITE IDENTIFICATION MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 102
TABLE 34 ASIA PACIFIC: SITE IDENTIFICATION MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 102
7.4 PATIENT RECRUITMENT 103
7.4.1 GROWING REQUIREMENT TO WORK WITH A PATIENT-CENTRIC CLINICAL TRIAL COMPANY SUPPORTS THE GROWTH OF THIS SEGMENT 103
TABLE 35 SOME OF THE PATIENT RECRUITMENT SERVICE PROVIDERS 103
TABLE 36 PATIENT RECRUITEMENT MARKET, BY REGION, 2019–2026 (USD BILLION) 104
TABLE 37 NORTH AMERICA: PATIENT RECRUITEMENT MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 104
TABLE 38 EUROPE: PATIENT RECRUITEMENT MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 104
TABLE 39 ASIA PACIFIC: PATIENT RECRUITEMENT MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 105
7.5 LABORATORY SERVICES 105
7.5.1 INCREASING IMPORTANCE OF LABORATORY SERVICES TO ENSURE REGULATORY COMPLIANCE PROPELS THE GROWTH OF THIS SEGMENT 105
TABLE 40 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS 105
TABLE 41 LABORATORY SERVICES MARKET, BY REGION, 2019–2026 (USD BILLION) 106
TABLE 42 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 106
TABLE 43 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 107
TABLE 44 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 107
7.5.2 ANALYTICAL TESTING SERVICES 107
7.5.2.1 Increasing demand for analytical testing for drug development to drive the growth of this segment 107
TABLE 45 ANALYTICAL TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD BILLION) 108
TABLE 46 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 108
TABLE 47 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 108
TABLE 48 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 109
7.6 BIOANALYTICAL TESTING SERVICES 109
7.6.1 HIGH DEMAND FOR BIOANALYTICAL TESTING DUE TO THE GROWING USE OF MACROMOLECULES AND BIOSIMILARS TO DRIVE THE GROWTH OF THIS SEGMENT 109
TABLE 49 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD BILLION) 110
TABLE 50 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD BILLION) 110
TABLE 51 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 110
TABLE 52 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 111
TABLE 53 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 111
7.6.2 CELL-BASED ASSAYS 111
7.6.2.1 Increasing number of service providers offering customized cell-based assay testing services to drive the growth of this segment 111
TABLE 54 CELL-BASED ASSAYS MARKET, BY REGION, 2019–2026 (USD BILLION) 112
TABLE 55 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 112
TABLE 56 EUROPE: CELL-BASED ASSAYS MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 112
TABLE 57 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 113
7.6.3 VIROLOGY TESTING 113
7.6.3.1 Higher uptake of in vitro virology assays in the development of antiviral pharmaceuticals to drive the growth of this segment 113
TABLE 58 VIROLOGY TESTING MARKET, BY REGION, 2019–2026 (USD BILLION) 113
TABLE 59 NORTH AMERICA: VIROLOGY TESTING MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 114
TABLE 60 EUROPE: VIROLOGY TESTING MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 114
TABLE 61 ASIA PACIFIC: VIROLOGY TESTING MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 114
7.6.4 PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES 115
7.6.4.1 Rising importance of studies to determine pharmacokinetic behavior of drug candidates to drive the growth of this segment 115
TABLE 62 PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY REGION, 2019–2026 (USD BILLION) 115
TABLE 63 NORTH AMERICA: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 116
TABLE 64 EUROPE: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 116
TABLE 65 ASIA PACIFIC: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 116
7.6.5 METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION 117
7.6.5.1 Increasing preference of biopharmaceutical companies to outsource method validation services for clinical trials to drive this segment 117
TABLE 66 METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET,
BY REGION, 2019–2026 (USD BILLION) 117
TABLE 67 NORTH AMERICA: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 118
TABLE 68 EUROPE: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 118
TABLE 69 ASIA PACIFIC: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 118
7.6.6 SEROLOGY, IMMUNOGENICITY, & NEUTRALIZING ANTIBODIES 119
7.6.6.1 High demand for immunogenicity and neutralizing antibody assays in biosimilar development to propel market growth 119
TABLE 70 SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET,
BY REGION, 2019–2026 (USD BILLION) 119
TABLE 71 NORTH AMERICA: SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 120
TABLE 72 EUROPE: SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 120
TABLE 73 ASIA PACIFIC: SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 120
7.6.7 BIOMARKER TESTING SERVICES 121
7.6.7.1 Growing emphasis on biomarker testing to develop personalized medicines and companion diagnostics to augment segment growth 121
TABLE 74 BIOMARKER TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD BILLION) 121
TABLE 75 NORTH AMERICA: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 121
TABLE 76 EUROPE: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 122
TABLE 77 ASIA PACIFIC: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 122
7.6.8 OTHER BIOANALYTICAL TESTING SERVICES 122
TABLE 78 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD BILLION) 123
TABLE 79 NORTH AMERICA: OTHER BIOANALYTICAL TESTING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD BILLION) 123
TABLE 80 EUROPE: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 123
TABLE 81 ASIA PACIFIC: OTHER BIOANALYTICAL TESTING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD BILLION) 124
7.7 CLINICAL TRIAL DATA MANAGEMENT SERVICES 124
7.7.1 DATA MANAGEMENT SERVICES SEGMENT IS EXPECTED TO RECORD
THE HIGHEST CAGR DURING THE FORECAST PERIOD 124
TABLE 82 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS 124
TABLE 83 CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY REGION,
2019–2026 (USD BILLION) 125
TABLE 84 NORTH AMERICA: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 126
TABLE 85 EUROPE: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD BILLION) 126
TABLE 86 ASIA PACIFIC: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD BILLION) 126
7.8 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES 127
7.8.1 ADVANCED DATA ANALYTICS INCORPORATED IN CLINICAL TRIAL SUPPLY MANAGEMENT IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT 127
TABLE 87 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY REGION,
2019–2026 (USD BILLION) 127
TABLE 88 NORTH AMERICA: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 127
TABLE 89 EUROPE: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD BILLION) 128
TABLE 90 ASIA PACIFIC: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD BILLION) 128
7.9 DECENTRALIZED CLINICAL TRIAL SERVICES 128
7.9.1 THE SARS-COV-2 OUTBREAK HAS SIGNIFICANTLY CATALYZED THE DEMAND FOR DECENTRALIZED CLINICAL TRIALS 128
TABLE 91 DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY REGION,
2019–2026 (USD BILLION) 129
TABLE 92 NORTH AMERICA: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD BILLION) 129
TABLE 93 EUROPE: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 129
TABLE 94 ASIA PACIFIC: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD BILLION) 130
7.10 MEDICAL DEVICE TESTING SERVICES 130
7.10.1 INCREASING R&D FOR THE DEVELOPMENT OF ADVANCED MEDICAL DEVICES TO DRIVE THE GROWTH OF THIS MARKET 130
TABLE 95 MEDICAL DEVICE TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD BILLION) 131
TABLE 96 NORTH AMERICA: MEDICAL DEVICE TESTING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD BILLION) 131
TABLE 97 EUROPE: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 131
TABLE 98 ASIA PACIFIC: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 132
7.11 OTHER CLINICAL TRIAL SERVICES 132
7.11.1 OTHER CLINICAL TRIAL SERVICES SEGMENT INCLUDES CONSULTING SERVICES, MEDICAL WRITING SERVICES, AND PHARMACOGENOMICS TESTING SERVICES 132
TABLE 99 OTHER CLINICAL TRIAL SERVICES MARKET, BY REGION,
2019–2026 (USD BILLION) 133
TABLE 100 NORTH AMERICA: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 133
TABLE 101 EUROPE: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 133
TABLE 102 ASIA PACIFIC: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 134
8 CLINICAL TRIALS MARKET, BY THERAPY AREA 135
8.1 INTRODUCTION 136
TABLE 103 CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION) 136
8.2 ONCOLOGY 136
8.2.1 RISING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH 136
FIGURE 31 GLOBAL CANCER INCIDENCE, BY TYPE (2020) 137
FIGURE 32 ONCOLOGY CLINICAL TRIALS GLOBALLY, 2010-2018 (THOUSAND) 138
TABLE 104 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020) 138
TABLE 105 CLINICAL TRIALS MARKET FOR ONCOLOGY, BY REGION,
2019–2026 (USD BILLION) 139
TABLE 106 NORTH AMERICA: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD BILLION) 139
TABLE 107 EUROPE: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY,
2019–2026 (USD BILLION) 140
TABLE 108 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD BILLION) 140
8.3 INFECTIOUS DISEASES 140
8.3.1 INFECTIOUS DISEASES SEGMENT TO REGISTER THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD 140
TABLE 109 CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY REGION,
2019–2026 (USD BILLION) 141
TABLE 110 NORTH AMERICA: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2019–2026 (USD BILLION) 141
TABLE 111 EUROPE: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2019–2026 (USD BILLION) 142
TABLE 112 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2019–2026 (USD BILLION) 142
8.4 NEUROLOGY 142
8.4.1 INCREASING INVESTMENTS IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH 142
TABLE 113 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020) 143
TABLE 114 CLINICAL TRIALS MARKET FOR NEUROLOGY, BY REGION,
2019–2026 (USD BILLION) 144
TABLE 115 NORTH AMERICA: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2019–2026 (USD BILLION) 144
TABLE 116 EUROPE: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY,
2019–2026 (USD BILLION) 144
TABLE 117 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2019–2026 (USD BILLION) 145
8.5 IMMUNOLOGY 145
8.5.1 GROWING PIPELINE OF IMMUNOLOGICAL DRUGS HAS RESULTED IN INCREASING OUTSOURCING ACTIVITIES 145
TABLE 118 CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY REGION,
2019–2026 (USD BILLION) 145
TABLE 119 NORTH AMERICA: CLINICAL TRIALS MARKET FOR IMMUNOLOGY,
BY COUNTRY, 2019–2026 (USD BILLION) 146
TABLE 120 EUROPE: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY,
2019–2026 (USD BILLION) 146
TABLE 121 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019–2026 (USD BILLION) 146
8.6 CARDIOLOGY 147
8.6.1 HIGH MORTALITY RATES ARE DRIVING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS 147
TABLE 122 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020) 147
TABLE 123 CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY REGION,
2019–2026 (USD BILLION) 148
TABLE 124 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2019–2026 (USD BILLION) 148
TABLE 125 EUROPE: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY,
2019–2026 (USD BILLION) 148
TABLE 126 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2019–2026 (USD BILLION) 149
8.7 GENETIC DISEASES 149
8.7.1 PROMISING DRUGS IN PIPELINE FOR RARE DISEASES TO SUPPORT MARKET GROWTH 149
TABLE 127 CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY REGION,
2019–2026 (USD BILLION) 150
TABLE 128 NORTH AMERICA: CLINICAL TRIALS MARKET FOR GENETIC DISEASES,
BY COUNTRY, 2019–2026 (USD BILLION) 150
TABLE 129 EUROPE: CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY COUNTRY, 2019–2026 (USD BILLION) 150
TABLE 130 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR GENETIC DISEASES,
BY COUNTRY, 2019–2026 (USD BILLION) 151
8.8 WOMEN’S HEALTH 151
8.8.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO DRIVE MARKET GROWTH 151
TABLE 131 CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY REGION,
2019–2026 (USD BILLION) 151
TABLE 132 NORTH AMERICA: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH,
BY COUNTRY, 2019–2026 (USD BILLION) 152
TABLE 133 EUROPE: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2019–2026 (USD BILLION) 152
TABLE 134 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH,
BY COUNTRY, 2019–2026 (USD BILLION) 152
8.9 OTHER THERAPY AREAS 153
FIGURE 33 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES,
2000-2045 (MILLION) 153
TABLE 135 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2020) 154
TABLE 136 CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS, BY REGION,
2019–2026 (USD BILLION) 154
TABLE 137 NORTH AMERICA: CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS,
BY COUNTRY, 2019–2026 (USD BILLION) 155
TABLE 138 EUROPE: CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS,
BY COUNTRY, 2019–2026 (USD BILLION) 155
TABLE 139 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS,
BY COUNTRY, 2019–2026 (USD BILLION) 155
9 CLINICAL TRIALS MARKET, BY APPLICATION 156
9.1 INTRODUCTION 157
TABLE 140 CLINICAL TRIAL MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 157
9.2 SMALL MOLECULE 157
9.2.1 INCREASING INVESTMENTS BY VIRTUAL AND SMALLER COMPANIES TO DRIVE SMALL MOLECULE DEVELOPMENT PROJECTS SUPPORTS
THE GROWTH OF THIS SEGMENT 157
FIGURE 34 SMALL MOLECULE PIPELINE: NEW CHEMICAL ENTITY, 2014-2019 158
TABLE 141 CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY REGION,
2019–2026 (USD BILLION) 158
TABLE 142 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2019–2026 (USD BILLION) 159
TABLE 143 EUROPE: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2019–2026 (USD BILLION) 159
TABLE 144 ASIA PACIFIC: CLINICAL TRIAL MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2019–2026 (USD BILLION) 159
9.3 VACCINES 160
9.3.1 OUTBREAK OF THE COVID-19 PANDEMIC IS EXPECTED TO EMERGE AS A MARKET DISRUPTOR, IMPOSING LONG-TERM POSITIVE EFFECTS ON
THE INDUSTRY OPERATIONS 160
FIGURE 35 COVID-19 VACCINE CANDIDATES IN CLINICAL DEVELOPMENT,
BY PHASE (AS OF JANUARY 2022) 161
TABLE 145 CLINICAL TRIALS MARKET FOR VACCINES, BY REGION,
2019–2026 (USD BILLION) 161
TABLE 146 NORTH AMERICA: CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2019–2026 (USD BILLION) 161
TABLE 147 EUROPE: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2019–2026 (USD BILLION) 162
TABLE 148 ASIA PACIFIC: CLINICAL TRIALS MARKET FORCLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2019–2026 (USD BILLION) 162
9.4 CELL & GENE THERAPY 162
9.4.1 THE RISING TREND OF OUTSOURCING SERVICES AND THE ONGOING EFFORTS OF SERVICE PROVIDERS TO EXPAND THEIR RESPECTIVE OFFERINGS IS DRIVING THE CLINICAL DEVELOPMENT PIPELINE FOR CELL & GENE THERAPY 162
FIGURE 36 ACTIVE CLINICAL TRIALS FOR CELL & GENE THERAPY,
BY INDICATION (AS OF 2020) 163
FIGURE 37 ACTIVE CLINICAL TRIALS FOR CELL & GENE THERAPY, BY PHASE (2020) 164
TABLE 149 CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY REGION,
2019–2026 (USD BILLION) 164
TABLE 150 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019–2026 (USD BILLION) 165
TABLE 151 EUROPE: CLINICAL TRIALS MARKET FORCLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019–2026 (USD BILLION) 165
TABLE 152 ASIA PACIFIC: CLINICAL TRIALS MARKET FORCLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019–2026 (USD BILLION) 165
9.5 OTHER APPLICATIONS 166
9.5.1 INCREASE IN R&D FOR THE DEVELOPMENT OF HORMONES AND BLOOD COMPONENTS SUPPORTS MARKET GROWTH 166
TABLE 153 CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY REGION, 2019–2026 (USD BILLION) 166
TABLE 154 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 167
TABLE 155 EUROPE: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 167
TABLE 156 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 167
10 CLINICAL TRIALS MARKET, BY REGION 168
10.1 INTRODUCTION 169
TABLE 157 CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION) 169
10.2 NORTH AMERICA 169
FIGURE 38 NORTH AMERICA SNAPSHOT 170
TABLE 158 NORTH AMERICA: CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 170
TABLE 159 NORTH AMERICA: CLINICAL TRIALS MARKET, BY PHASE,
2019–2026 (USD BILLION) 171
TABLE 160 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET,
BY SERVICE TYPE, 2019–2026 (USD BILLION) 171
TABLE 161 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET,
BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION) 172
TABLE 162 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET,
BY THERAPY AREA, 2019–2026 (USD BILLION) 172
TABLE 163 NORTH AMERICA: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION) 173
10.2.1 US 173
10.2.1.1 Robust clinical research activities to become a key factor supporting the US market growth 173
FIGURE 39 US CONTINUES TO DOMINATE THE DISTRIBUTION OF R&D COMPANIES
BY REGION (2020 VS. 2019) 174
TABLE 164 US: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 174
TABLE 165 US: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION) 175
TABLE 166 US: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION) 175
TABLE 167 US: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION) 176
TABLE 168 US: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 176
10.2.2 CANADA 176
10.2.2.1 Increasing number of clinical trials in Canada to support market growth 176
TABLE 169 CANADA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 177
TABLE 170 CANADA: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION) 177
TABLE 171 CANADA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION) 178
TABLE 172 CANADA: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION) 178
TABLE 173 CANADA: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION) 179
10.3 EUROPE 179
FIGURE 40 CLINICAL TRIALS CONDUCTED IN EUROPE SINCE 2008 (2018) 180
TABLE 174 EUROPE: CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 180
TABLE 175 EUROPE: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 180
TABLE 176 EUROPE: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION) 181
TABLE 177 EUROPE: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION) 181
TABLE 178 EUROPE: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION) 182
TABLE 179 EUROPE: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION) 182
10.3.1 GERMANY 182
10.3.1.1 Government support and flexible labor laws have made Germany a favorable location for clinical trials 182
TABLE 180 GERMANY: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 183
TABLE 181 GERMANY: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION) 183
TABLE 182 GERMANY: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION) 184
TABLE 183 GERMANY: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION) 184
TABLE 184 GERMANY: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION) 185
10.3.2 UK 185
10.3.2.1 Investments by pharmaceutical sponsors in the UK for drug discovery services to support market growth 185
FIGURE 41 UK: PHARMACEUTICAL R&D EXPENDITURE, 2013–2017 (USD MILLION) 186
TABLE 185 UK: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 186
TABLE 186 UK: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION) 187
TABLE 187 UK: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION) 187
TABLE 188 UK: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION) 188
TABLE 189 UK: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 188
10.3.3 FRANCE 188
10.3.3.1 High number of oncology clinical trials in France is expected to drive market growth in France 188
TABLE 190 FRANCE: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 189
TABLE 191 FRANCE: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION) 189
TABLE 192 FRANCE: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION) 190
TABLE 193 FRANCE: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION) 190
TABLE 194 FRANCE: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION) 191
10.3.4 ITALY 191
10.3.4.1 Low drug approval times along with the growing number of clinical trials in Italy to drive market growth 191
TABLE 195 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021) 191
TABLE 196 ITALY: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 192
TABLE 197 ITALY: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION) 192
TABLE 198 ITALY: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION) 193
TABLE 199 ITALY: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION) 193
TABLE 200 ITALY: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION) 194
10.3.5 SPAIN 194
10.3.5.1 Rising R&D expenditure to boost market growth for clinical trials
in Spain 194
FIGURE 42 SPAIN: PHARMACEUTICAL R&D EXPENDITURE (USD MILLION), 2011–2017 195
TABLE 201 SPAIN: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 195
TABLE 202 SPAIN: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION) 196
TABLE 203 SPAIN: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION) 196
TABLE 204 SPAIN: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION) 197
TABLE 205 SPAIN: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION) 197
10.3.6 REST OF EUROPE (ROE) 198
TABLE 206 ROE: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 199
TABLE 207 ROE: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION) 199
TABLE 208 ROE: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION) 200
TABLE 209 ROE: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION) 200
TABLE 210 ROE: CLINICAL TRIALS MARKET, BY MOLECULE, 2019–2026 (USD BILLION) 201
10.4 ASIA PACIFIC (APAC) 201
FIGURE 43 ASIA PACIFIC SNAPSHOT 202
TABLE 211 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION) 202
TABLE 212 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY PHASE,
2019–2026 (USD BILLION) 203
TABLE 213 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION) 203
TABLE 214 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION) 204
TABLE 215 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION) 204
TABLE 216 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION) 205
10.4.1 CHINA 205
10.4.1.1 China dominates the clinical trials services market owing to a robust pharmaceutical industry and presence of prominent clinical trial service providers 205
TABLE 217 CHINA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 206
TABLE 218 CHINA: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION) 206
TABLE 219 CHINA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION) 207
TABLE 220 CHINA: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION) 207
TABLE 221 CHINA: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION) 208
10.4.2 JAPAN 208
10.4.2.1 Strong focus on R&D activities in Japan is expected to drive market growth 208
TABLE 222 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA,
2017 VS. 2019 208
TABLE 223 JAPAN: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 209
TABLE 224 JAPAN: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION) 209
TABLE 225 JAPAN: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION) 210
TABLE 226 JAPAN: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION) 210
TABLE 227 JAPAN: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION) 211
10.4.3 INDIA 211
10.4.3.1 Growing pharmaceutical industry in India to drive the market growth for clinical trails 211
TABLE 228 TOTAL NUMBER OF CLINICAL TRIALS IN INDIA, BY THERAPEUTIC AREA,
2017 VS. 2019 211
TABLE 229 INDIA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 212
TABLE 230 INDIA: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION) 212
TABLE 231 INDIA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION) 213
TABLE 232 INDIA: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION) 213
TABLE 233 INDIA: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION) 214
10.4.4 REST OF ASIA PACIFIC 214
TABLE 234 TOTAL NUMBER OF CLINICAL TRIALS IN SINGAPORE AND MALAYSIA,
BY THERAPEUTIC AREA, 2017 VS. 2019 214
TABLE 235 ROAPAC: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 215
TABLE 236 ROAPAC: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION) 215
TABLE 237 ROAPAC: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION) 216
TABLE 238 ROAPAC: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION) 216
TABLE 239 ROAPAC: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION) 217
10.5 LATIN AMERICA 217
10.5.1 GROWING R&D EXPENDITURE IN THE PHARMACEUTICAL & BIOPHARMACEUTICAL SECTOR TO DRIVE THE MARKET
GROWTH IN LATIN AMERICA 217
TABLE 240 LATIN AMERICA: CLINICAL TRIALS MARKET, BY PHASE,
2019–2026 (USD BILLION) 218
TABLE 241 LATIN AMERICA: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION) 218
TABLE 242 LATIN AMERICA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION) 219
TABLE 243 LATIN AMERICA: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION) 219
TABLE 244 LATIN AMERICA: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION) 220
10.6 MIDDLE EAST & AFRICA 220
10.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE THE MARKET GROWTH IN MIDDLE EAST & AFRICA 220
TABLE 245 MEA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 221
TABLE 246 MEA: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION) 221
TABLE 247 MEA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION) 222
TABLE 248 MEA: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION) 222
TABLE 249 MEA: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION) 223
11 COMPETITIVE LANDSCAPE 224
11.1 INTRODUCTION 224
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 224
FIGURE 44 CLINICAL TRIALS MARKET: STRATEGIES ADOPTED 225
11.3 MARKET SHARE ANALYSIS 226
FIGURE 45 CLINICAL TRIALS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2020) 226
11.4 COMPANY EVALUATION QUADRANT 228
11.4.1 STARS 228
11.4.2 EMERGING LEADERS 228
11.4.3 PERVASIVE PLAYERS 228
11.4.4 PARTICIPANTS 228
FIGURE 46 CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX, 2020 229
11.5 COMPETITIVE BENCHMARKING 230
11.5.1 COMPANY SERVICE FOOTPRINT (20 COMPANIES) 230
FIGURE 47 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE CLINICAL TRIALS MARKET 230
11.5.2 COMPANY REGIONAL FOOTPRINT (20 COMPANIES) 231
FIGURE 48 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE CLINICAL TRIALS MARKET 231
11.6 COMPETITIVE SCENARIO AND TRENDS 232
11.6.1 SERVICES LAUNCHES 232
TABLE 250 CLINICAL TRIALS MARKET: SERVICE LAUNCHES
(JANUARY 2017-NOVEMBER 2020) 232
11.6.2 DEALS 233
TABLE 251 CLINICAL TRIALS MARKET: DEALS (JANUARY 2017-SEPTEMBER 2021) 233
11.6.3 OTHER DEVELOPMENTS 234
TABLE 252 CLINICAL TRIALS MARKET: EXPANSIONS (JANUARY 2017-NOVEMBER 2020) 234
12 COMPANY PROFILES 235
12.1 KEY COMPANIES 235
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 IQVIA 235
TABLE 253 IQVIA: BUSINESS OVERVIEW 235
FIGURE 49 IQVIA: COMPANY SNAPSHOT 236
TABLE 254 IQVIA: SERVICE OFFERINGS 236
TABLE 255 IQVIA: SERVICE LAUNCHES 237
TABLE 256 IQVIA: DEALS 238
TABLE 257 IQVIA: OTHER DEVELOPMENTS 238
12.1.2 LABCORP DRUG DEVELOPMENT (COVANCE) 240
TABLE 258 LABCORP: BUSINESS OVERVIEW 240
FIGURE 50 LABCORP: COMPANY SNAPSHOT 241
TABLE 259 LABCORP: SERVICE OFFERINGS 241
TABLE 260 LABCORP: SERVICE LAUNCHES 242
TABLE 261 LABCORP: DEALS 243
TABLE 262 LABCORP: EXPANSIONS 244
12.1.3 SYNEOS HEALTH INC. 246
TABLE 263 SYNEOS HEALTH INC.: BUSINESS OVERVIEW 246
FIGURE 51 SYNEOS HEALTH INC.: COMPANY SNAPSHOT 246
TABLE 264 SYNEOS HEALTH INC.: SERVICE OFFERINGS 247
TABLE 265 SYNEOS HEALTH INC: SERVICE LAUNCHES 248
TABLE 266 SYNEOS HEALTH INC.: DEALS 248
12.1.4 WUXI APPTEC 252
TABLE 267 WUXI APPTEC: BUSINESS OVERVIEW 252
FIGURE 52 WUXI APPTEC: COMPANY SNAPSHOT 253
TABLE 268 WUXI APPTEC: SERVICE OFFERINGS 253
TABLE 269 WUXI APPTEC: SERVICE LAUNCHES 255
TABLE 270 WUXI APPTEC: DEALS 256
TABLE 271 WUXI APPTEC: EXPANSIONS 257
12.1.5 CHARLES RIVER LABORATORIES 259
TABLE 272 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW 259
FIGURE 53 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT 260
TABLE 273 CHARLES RIVER LABORATORIES: SERVICE OFFERINGS 260
TABLE 274 CHARLES RIVER LABORATORIES: DEALS 261
TABLE 275 CHARLES RIVER LABORATORIES: EXPANSIONS 263
12.1.6 PAREXEL INTERNATIONAL 265
TABLE 276 PAREXEL INTERNATIONAL: BUSINESS OVERVIEW 265
TABLE 277 PAREXEL INTERNATIONAL: SERVICE OFFERINGS 265
TABLE 278 PAREXEL INTERNATIONAL: SERVICE LAUNCHES 267
TABLE 279 PAREXEL INTERNATIONAL: DEALS 268
TABLE 280 PAREXEL INTERNATIONAL: EXPANSIONS 270
12.1.7 PRA HEALTH SCIENCES 271
TABLE 281 PRA HEALTH SCIENCES: BUSINESS OVERVIEW 271
FIGURE 54 PRA HEALTH SCIENCES: COMPANY SNAPSHOT 272
TABLE 282 PRA HEALTH SCIENCES: SERVICE OFFERINGS 272
TABLE 283 PRA HEALTH SCIENCES: SERVICE LAUNCHES 272
TABLE 284 PRA HEALTH SCIENCES: DEALS 273
TABLE 285 PRA HEALTH SCIENCES: EXPANSIONS 274
12.1.8 PPD INC 275
TABLE 286 PPD INC: BUSINESS OVERVIEW 275
FIGURE 55 PPD INC: COMPANY SNAPSHOT 276
TABLE 287 PPD INC: SERVICE OFFERINGS 276
TABLE 288 PPD: SERVICE LAUNCHES 277
TABLE 289 PPD: DEALS 278
TABLE 290 PPD: EXPANSIONS 280
12.1.9 ICON PLC 281
TABLE 291 ICON PLC: BUSINESS OVERVIEW 281
FIGURE 56 ICON PLC: COMPANY SNAPSHOT 281
TABLE 292 ICON PLC: SERVICE OFFERINGS 282
TABLE 293 ICON PLC : SERVICE LAUNCHES 285
TABLE 294 ICON PLC: DEALS 285
12.1.10 MEDPACE HOLDINGS INC 287
TABLE 295 MEDPACE HOLDINGS INC: BUSINESS OVERVIEW 287
FIGURE 57 MEDPACE HOLDINGS INC: COMPANY SNAPSHOT 287
TABLE 296 MEDPACE HOLDINGS INC: SERVICE OFFERINGS 288
TABLE 297 MEDPACE HOLDINGS INC: DEALS 288
TABLE 298 MEDPACE HOLDINGS INC: EXPANSION 288
12.1.11 ACM GLOBAL LABORATORIES 289
TABLE 299 ACM GLOBAL LABORATORIES: BUSINESS OVERVIEW 289
TABLE 300 ACM GLOBAL LABORATORIES: SERVICE OFFERINGS 289
12.1.12 ADVANCED CLINICAL 291
TABLE 301 ADVANCED CLINICAL: BUSINESS OVERVIEW 291
TABLE 302 ADVANCED CLINICAL: SERVICE OFFERINGS 291
12.1.13 SGS 293
TABLE 303 SGS: BUSINESS OVERVIEW 293
FIGURE 58 SGS: COMPANY SNAPSHOT 294
TABLE 304 SGS: SERVICE OFFERINGS 294
TABLE 305 SGS: DEALS 295
12.1.14 FRONTAGE HOLDINGS CORPORATION 296
TABLE 306 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW 296
FIGURE 59 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT 297
TABLE 307 FRONTAGE HOLDINGS CORPORATION: SERVICE OFFERINGS 297
TABLE 308 FRONTAGE HOLDINGS CORPORATION: DEALS 298
TABLE 309 FRONTAGE HOLDINGS CORPORATION: EXPANSION 299
12.1.15 PSI CRO AG 300
TABLE 310 PSI CRO AG: BUSINESS OVERVIEW 300
TABLE 311 PSI CRO AG: SERVICE OFFERINGS 300
TABLE 312 PSI CRO AG: EXPANSIONS 300
12.1.16 BIO AGILE THERAPEUTICS 301
TABLE 313 BIO AGILE THERAPEUTICS: BUSINESS OVERVIEW 301
TABLE 314 BIO AGILE THERAPEUTICS: SERVICE OFFERINGS 301
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS 303
12.2.1 AZELIX 303
TABLE 315 AZELIX: COMPANY OVERVIEW 303
12.2.2 CTSERV 304
TABLE 316 CTSERV: COMPANY OVERVIEW 304
12.2.3 PEPGRA 304
TABLE 317 PEPGRA: COMPANY OVERVIEW 304
12.2.4 AXCENT ADVANCED ANALYTICS (A3) 305
TABLE 318 AXCENT ADVANCED ANALYTICS (A3): COMPANY OVERVIEW 305
12.2.5 DOVE QUALITY SOLUTIONS 306
TABLE 319 DOVE QUALITY SOLUTIONS: COMPANY OVERVIEW 306
12.2.6 FIRMA CLINICAL RESEARCH 306
TABLE 320 FIRMA CLINICAL RESEARCH: COMPANY OVERVIEW 306
12.2.7 CELERION 307
TABLE 321 CELERION: COMPANY OVERVIEW 307
12.2.8 NOVOTECH HEALTH HOLDINGS 308
TABLE 322 NOVOTECH HEALTH HOLDINGS: COMPANY OVERVIEW 308
12.2.9 GENETICIST INC. 308
TABLE 323 GENETICIST INC.: COMPANY OVERVIEW 308
12.2.10 LINICAL AMERICAS 309
TABLE 324 LINICAL AMERICAS: COMPANY OVERVIEW 309
13 APPENDIX 310
13.1 DISCUSSION GUIDE 310
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 313
13.3 AVAILABLE CUSTOMIZATIONS 315
13.4 RELATED REPORT 316
13.5 AUTHOR DETAILS 317